MMP9 and cancer: More recently, the same group developed a low molecular weight compound that specifically binds to the PEX domain of MMP-9 and abolishes its homodimerization, blocking the CD44-AGFR-MAKP signaling pathway38 and thus interfering with MMP-9-mediated cancer cell proliferation, migration, and invasion.39